title: Topographic EEG studies of mania.
abstract: QEEG findings from 39 hospitalized manic patients were accomplished after a drug free period and following pharmacotherapy with lithium or carbamazepine alone or lithium combined with carbamazepine, haloperidol or risperidone. A subsample of 10 drug-free manic patients was compared with normal controls, which revealed lower qEEG amplitudes in the left anterior and midtemporal regions in the patients. Comparisons of drug therapies showed increased delta amplitudes and total power with lithium compared with carbamazepine. Increased fast frequencies were observed in the lithium and carbamazepine plus lithium groups compared with carbamazepine alone. Comparisons of the three drug combination groups revealed increased alpha and beta 1 amplitudes, most with risperidone and least with carbamazepine. Anterior delta and beta 2 amplitudes and interhemispheric coherence were increased directly proportional to plasma lithium levels. Nonresponders to treatment were identified at baseline by increased generalized theta amplitudes. After treatment, the nonresponders had higher amplitudes in the left temporal areas. Numerous qEEG associations with individual ratings of manic symptoms were found, more at baseline than after treatment. In general levels of psychopathology were negatively correlated with qEEG amplitudes. The qEEG findings appear to implicate dominant temporal lobe dysfunctions in mania.
authors.affiliation: Department of Psychiatry, Indiana University School of Medicine, Larue D. Carter Memorial Hospital, Indianapolis 46222-2202, USA.
authors.forename: J G
authors.initials: JG
authors.lastname: Small
authors.forename: V
authors.initials: V
authors.lastname: Milstein
authors.forename: F W
authors.initials: FW
authors.lastname: Malloy
authors.forename: M H
authors.initials: MH
authors.lastname: Klapper
authors.forename: S J
authors.initials: SJ
authors.lastname: Golay
authors.forename: C E
authors.initials: CE
authors.lastname: Medlock
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy / Q000503:physiopathology*; D002220:Carbamazepine / Q000627:therapeutic use; D004569:Electroencephalography; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
chemical_list: D014150:Antipsychotic Agents; D002220:Carbamazepine; D008094:Lithium; D006220:Haloperidol